Real‐world results with IgPro20 for hypo‐ or agammaglobulinemia in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Pediatrics International"
DOI: 10.1111/ped.15362
Abstract: Abstract Background Subcutaneous immunoglobulin is one of the standard treatments for hypogammaglobulinemia in primary immunodeficiencies (PID) worldwide. In Japan, IgPro20 (Hizentra®; l‐proline‐stabilized 20% human subcutaneous immunoglobulin) is approved for agammaglobulinemia or hypogammaglobulinemia due to PID… read more here.
Keywords: sid; pid sid; due pid; japan ... See more keywords